Stocks · News reference
Analysts Update Ratings and Price Targets for ArriVent BioPharma
Several financial analysts maintained buy ratings and updated price targets for ArriVent BioPharma (AVBP) on November 11, 2026.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
BTIG Maintains Buy Rating and $29 Price Target for ArriVent BioPharma
BTIG analyst Jeet Mukherjee has reiterated a Buy rating and a $29.00 price target on ArriVent BioPharma, Inc.
Cantor Fitzgerald Reiterates Overweight Rating for ArriVent BioPharma
Cantor Fitzgerald reaffirmed an Overweight rating for ArriVent BioPharma, Inc. on November 12, 2026.
Truist Securities Raises Price Target for ArriVent BioPharma
Truist Securities has maintained its 'Buy' rating on ArriVent BioPharma while increasing the price target from $21.00 to $24.00 per share.
Truist Securities Maintains Buy on ArriVent BioPharma, Raises Price Target to $24
ArriVent BioPharma Reports Third Quarter 2026 Financial Results
ArriVent BioPharma announced its financial results for the third quarter ended September 30, 2026, and provided updates on its clinical pipeline, including the ALPACCA trial and ARR-217.